

Oncology Today with Dr Neil Love: New Targets in Non-Small Cell Lung Cancer (Presentation Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is FALSE about capmatinib for patients with metastatic non-small cell lung cancer (NSCLC)?**
 - It is FDA approved for patients with MET exon 14 skipping mutations
 - It has not demonstrated good CNS penetration
 - It has been associated with edema
- 2. Which of the following statements is true regarding the FDA approval of selpercatinib for patients with metastatic NSCLC?**
 - It applies to all patients with metastatic NSCLC
 - It applies only to disease with RET fusion
 - It applies only to treatment-naïve disease with RET fusion
- 3. Tepotinib has recently received FDA approval for patients with metastatic NSCLC with which of the following genomic alterations?**
 - EGFR mutations
 - RET fusions
 - MET exon 14 skipping mutations
- 4. The antibody-drug conjugate trastuzumab deruxtecan has been associated with which of the following unique side effects in patients with NSCLC and HER2 alterations?**
 - Central serous retinopathy
 - QT interval prolongation
 - Pneumonitis/interstitial lung disease